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ReviewThe Flip Side: Identifying Small
Molecule Regulators
of Nuclear Receptors
The LBD crystal structures confirm molecular and bio-
chemical studies indicating that ligand binding pro-
motes a conformational change in NR structure (Figure
1B). What appears to be a relatively flexible conserved
helix near the carboxyl terminus (helix 12) occupies
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unique positions when structures of unliganded, agonist-
occupied, and antagonist-occupied LBDs are compared
(Figure 2) [6–8]. Importantly, mutagenesis experiments
Members of the nuclear hormone receptor superfamily
indicate that helix 12 is necessary for ligand-dependent
function as ligand-activated transcription factors to
transactivation by nuclear receptors [9]. Recent work
regulate genetic networks controlling cell growth and
indicates that helix 12 contributes an essential surface
differentiation, inflammatory responses, and metabo-
to the formation of an agonist-dependent hydrophobic
lism. The ability to modulate nuclear receptor-depen-
groove comprised of amino acids from helices 3, 4, 5,
dent gene expression with small molecules has made
6, and 12 that serves as a binding site for coactivators
the superfamily a favored target for drug discovery.
[10]. The alternative positions occupied by helix 12 in
Not surprisingly, small molecules that regulate recep-
the unliganded or antagonist-occupied conformations
tor activity are currently used to treat a number of
preclude the formation of this binding groove and in-
human disorders. Over the last 10 years, the availability
stead favor the binding of corepressors to a region that
of a common platform of functional assays suitable
overlaps the coactivator binding site (Figure 2). As their
for any nuclear receptor has facilitated the identifica-
name implies, corepressors function as inhibitors of
tion of endogenous and synthetic ligands that have
transcription when complexed with unliganded or an-
been used as tools to uncover previously unantici-
tagonist-occupied NRs [11]. Thus, by modulating pro-
pated endocrine signaling pathways. Recent progress
tein-protein interactions, a conformational change in-
in understanding the molecular basis for ligand-
duced by the binding of hormones or synthetic small
dependent gene regulation suggests that a new era of
molecule ligands is translated into a transcriptional
“designer” ligands with tissue- and/or gene-selective
response.
activity will quickly be upon us.
Numerous NR coactivators and corepressors have
been identified using two-hybrid screens and in vitro
protein-protein interaction assays [12]. Interestingly, as
The Nuclear Receptor Superfamily a group the ability of NR coactivators and corepressors
Analysis of genome sequences has identified 48 human (collectively referred to as coregulators) to interact with
members of the steroid and thyroid nuclear hormone receptors in a ligand-dependent manner is mediated
receptor superfamily [1]. Nuclear receptors (NRs) func- by relatively small hydrophobic  helical sequences. In
tion as ligand-dependent transcription factors that regu- particular, many coactivators utilize a common signa-
late the activity of genetic networks essential for the ture motif, LxxLL (L  leucine, x  any amino acid),
proper control of development, differentiation, and ho- present once or up to several times, to interact with
meostasis. The important roles played by NRs in human NRs. These LxxLL motifs have also been referred to as
physiology and the ability to regulate their functional NR boxes [13, 14]. When receptor-coregulator interac-
activity with synthetic small molecule mimics of natural tions have been examined, individual NRs exhibit dis-
ligands has long stimulated the interest of the pharma- tinct but overlapping preferences [15, 16]. As described
ceutical industry. Indeed, synthetic ligands for NRs are below, the ability to measure ligand-dependent interac-
currently used to treat a host of human diseases includ- tions between NRs and relatively small LxxLL containing
ing cancer [2], inflammation [3], and metabolic syn- peptides has been exploited for the identification of
dromes [4]. novel NR ligands.
Admission into the NR superfamily requires an evolu-
tionary conserved primary structure (Figure 1A) com-
prised of a variable amino-terminal domain, a highly Identification of Nuclear Receptor Ligands
conserved DNA binding domain (DBD) that includes two The structural and mechanistic conservation within the
zinc-coordinating motifs, and a less well-conserved li- NR superfamily has allowed the development of a com-
gand binding domain (LBD) [5]. The LBD is functionally mon platform of assays that have been used for ligand
complex and mediates receptor dimerization, ligand identification (Figures 3 and 4). Well-known signaling
binding, and ligand-dependent transcriptional regula- molecules such as steroids, thyroid hormone, vitamin
tion. While many NRs were identified based upon pri- D, and retinoic acid were shown to interact with specific
mary sequence homology to receptor DBDs, recent NRs by direct binding assays with radiolabeled ligands.
structural analysis of receptor LBDs has revealed a Additionally, these hormonal signaling molecules were
highly conserved 3-dimensional fold comprised of 12  used to regulate receptor transcriptional activity in func-
helices sandwiched around two  sheets (Figure 1B) [6–8]. tional assays that entail cotransfection of receptor ex-
pression plasmids and reporter plasmids linked to cis-
acting DNA binding sites (hormone response elements,*Correspondence: ischulman@x-ceptor.com
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Figure 1. Conserved Structure of the Nuclear
Receptor Superfamily
(A) Members of the nuclear receptor super-
family are characterized by a conserved
structure that includes a variable amino-ter-
minal domain, a highly conserved DNA bind-
ing domain that consists of two zinc binding
domains, and the ligand binding domain
(LBD). The LBD mediates ligand binding, re-
ceptor dimerization, transcriptional repres-
sion, and transcriptional activation.
(B) Structure of the RXR LBD in the absence
(apo) [51] and presence (holo) [52] of 9-cis
retinoic acid. Note the change in the position
of helix 12 (orange) upon ligand binding.
HREs) into mammalian cells. The cotransfection assay in a high throughput fashion, allowing the analysis of
large numbers of compounds and facilitating the gener-reconstitutes a functional hormone response unit com-
ation of detailed dose-response curves. Antagonist ac-prised of the receptor of interest bound to an HRE (usu-
tivity can also be measured by activating the receptorally multiple copies of an HRE sequence are arrayed in
of interest with an agonist and quantitating decreasestandem; Figure 3A) upstream of a reporter gene that
in reporter activity upon addition of increasing concen-encodes an enzyme such as luciferase or -galactosi-
trations of antagonists.dase that can easily be quantitated [5]. Treatment of
In recent years the traditional cotransfection assaytransfected cells with receptor-selective agonists in-
has been extended to include the use of fusions betweencreases the transcriptional activity of the receptor, re-
NR LBDs and the DNA binding domain of the yeastsulting in increased levels of the mRNA encoding the
transcription factor GAL4 (Figure 3B) and two-hybridreporter enzyme, and the elevated levels of mRNA of
assays that detect ligand-dependent NR-coregulator in-the reporter enzyme lead to increased enzymatic activity
teractions (Figure 3C). The GAL4 fusion assay is similarthat can be detected in whole-cell lysates. Such trans-
to the traditional assay described above; however, infection assays can easily be automated and carried out
this system the LBD of a receptor is fused to a DNA
binding domain of a yeast transcription factor that does
not have a ortholog in mammalian genomes. The GAL4
fusion is then transfected into cells along with a reporter
gene containing three to five GAL4 binding sites. Taking
advantage of the “foreign” yeast DNA binding domain
limits interference from endogenous DNA binding pro-
teins and other nuclear receptors that can bind to mam-
malian HRE sequences and many times results in assays
with a larger dynamic range of sensitivity.
Like the GAL4 assay, two-hybrid assays also utilize
artificially created fusion proteins. In this case the recep-
tor interacting domain(s) of coregulators are fused to
the GAL4 DNA binding domain while receptor LBDs are
fused to a strong constitutively active transcriptional
activation domain such as the well-characterized activa-
tion domain of the viral transcription factor VP16. The
GAL4-coregulator fusion binds to the reporter gene but
by itself does not activate transcription. Similarly, the
receptor VP16-LBD fusion does not bind to the reporter,
which only contains GAL4 binding sites. If the GAL4
fusion protein is derived from a coactivator, addition
of agonists promotes a conformational change in the
receptor LBD, allowing interaction with the DNA bound
coactivator. This protein-protein interaction brings the
strong VP16 activation domain to the reporter, resulting
in increased transcription of the reporter gene that is
Figure 2. Agonists and Antagonists Promote Different Receptor read out as increased enzymatic activity. In contrast,
Conformations
if the GAL4 fusion is derived from a corepressor that
Agonist binding results in a repositioning of helix 12 near amino
interacts with unliganded receptors, reporter activity isacid residues from helices 3, 4, 5, and 6, creating a groove for
high in the absence of ligands and low when the recep-coactivator binding. Antagonist binding sterically inhibits the ability
tor-corepressor interaction is disrupted by agonist treat-of helix 12 to form the active conformation. Instead, helix 12 occu-
pies a position that covers coactivator binding. ment. Along with the two-hybrid assays described
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Figure 3. Cell-Based Assays for Nuclear
Receptor Function
(A) Classic cotransfection assays that mea-
sure activity of nuclear receptors on hormone
response elements. Receptors can function
as heterodimers with RXR (shown), as homo-
dimers, or as monomers.
(B) GAL4-receptor LBD assay utilizes the
DNA binding domain of the yeast transcrip-
tion factor GAL4 to target the LBD to a re-
porter with GAL4 binding sites.
(C) Two-hybrid assays comprising coregula-
tor receptor-interacting domains fused to the
GAL4 DNA binding domain, and receptors
(LBDs or full-length) fused to the strong trans-
activation domain of the viral protein VP16.
Ligand-dependent interactions between re-
ceptor and coregulator tether the VP16 acti-
vation domain to the promoter, resulting in
activation of the reporter gene.
above, the ability to detect ligand-dependent interac- could directly regulate gene expression. Nevertheless,
the nuclear receptor field was left with a perplexingtions between NRs and short sequence motifs derived
from coregulator boxes has allowed the development of question. What are the ligands and physiological func-
tions for the remaining 75% of the superfamily that werebiochemical-based time-resolved fluorescence energy
transfer [17, 18] and fluorescence polarization assays identified by DNA sequence homology? These receptors
with no known ligand or function were classified as “or-[19] (Figure 4) that utilize recombinant receptors (usually
LBDs) and synthetic peptides (7 to 25 amino acids in phan” receptors. Over the last ten years a combination
of molecular, genetic, and biochemical approacheslength). Like the two-hybrid assays, these biochemical
assays monitor the ability of ligands to modulate protein- along with the nuclear receptor platform assays de-
scribed in Figures 3 and 4 have been used to identifyprotein interactions (see Figure 4 for more details).
ligands for orphan receptors and uncover new signaling
pathways [20]. Three examples of the approaches usedOrphan Receptor Ligands: The Early Years
The linkage of classically defined signaling molecules are illustrated by the retinoid X receptors (RXR), the
peroxisome proliferator activated receptor  (PPAR),such as steroid and thyroid hormones, vitamin A, and
vitamin D to cDNA sequences encoding NRs during the and the liver X receptors (LXRs).
RXR was originally cloned via homology to the DNAlate 1980s and early 1990s revealed a new regulatory
paradigm by which hormones and small molecules binding domain of the retinoic acid receptor  (RAR).
Figure 4. Biochemical Assays for Nuclear
Receptor Function
(A) Time-resolved fluorescence resonance
energy transfer. Interaction between labeled
recombinant receptor (fluorescently tagged
via an antibody to GST) and an LxxLL con-
taining peptide labeled with a second fluores-
cent tag results in energy transfer from recep-
tor to the peptide upon excitation with
appropriate wavelength of light when the two
tags are in close proximity. The tag on the
peptide only releases light when excited by
energy released from the tag on the receptor.
(B) Fluorescence polarization. Interaction be-
tween recombinant receptor and fluores-
cently tagged peptide results in a decrease
in the rate of rotation of the peptide and a
change in polarization.
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A ligand hunt utilizing a cotransfection assay in mamma- lism via the LXRs, control of bile acid and triglyceride
metabolism via the farnesoid X receptor (FXR) [32, 33],lian tissue culture cells led to the surprising finding that
all-trans retinoic acid, a vitamin A derivative already and control of xenobiotic metabolism via the pregnane X
receptor (PXR/SXR) [34] and constitutive active receptordefined as a high-affinity ligand for the RARs, increased
the transcriptional activity of RXR in a dose-dependent (CAR) [35]. This process of using the cloned NR as an
entryway into uncharacterized signaling systems hasmanner. Direct binding of all-trans retinoic acid to RXR,
however, could not be detected [21]. Subsequent bio- been termed reverse endocrinology [36]. Interestingly,
many of the putative endogenous ligands identified arechemical fractionation of extracts from cells treated with
all-trans retinoic acid led to the identification of 9-cis relatively low-affinity (micromolar) and this has led to
the suggestion that improved and more sensitive assaysretinoic acid as a high-affinity ligand for both RXR and
the RARs [22, 23]. Further characterization of the RXRs are needed for the identification of naturally occurring
high-affinity ligands that may be present at low concen-( and  iso-types were also discovered) identified these
receptors as common heterodimeric binding partners of trations or exist only transiently. Nevertheless, several
of these low-affinity endogenous ligands such as fattya large percentage of the receptor superfamily including
many of the orphans [24]. acids (PPAR ligands) and bile acids (FXR ligands) are
present at concentrations that approximate their kd forBiochemical and functional studies defined the or-
phan receptor PPAR as a master regulator of the ge- receptor binding. The concordance between receptor
kd and ligand concentration supports the hypothesisnetic program leading to adipocyte differentiation [25].
The discovery of a biological role for this orphan recep- that such receptors are poised to alter gene expression
in response to small changes in ligand concentrationtor dovetailed nicely with a successful ligand hunt for
PPAR, again using transient transfection assays that and thus function as sensors that respond to changes
in food intake and metabolic status. Clearly, further defi-identified 15-deoxy-12,14-prostaglandin J2 as a low-
affinity ligand (micromolar EC50) [26]. These authors also nition of the signaling pathways regulated by the
adopted orphans will be needed in order to determineshowed that activation of PPAR with 15-deoxy-12,14-
PDJ2 promotes adipogenesis in cultured cells. Interest- if endogenous ligands that approach the affinities of the
classically defined NR hormones exist.ingly, previous studies had demonstrated that the thia-
zolidinediones (TZDs), a class of potent synthetic insu- Along with the identification of endogenous ligands,
the ability to configure the NR platform assays in a highlin-sensitizing agents currently in use for the treatment
of type II diabetes, also promote adipogenesis. These throughput format has allowed the screening of large
libraries of structurally diverse synthetic compounds fortwo observations dramatically came together when it
was demonstrated that TZDs are ligands for PPARwith nuclear receptor ligands. Following optimization using
traditional medicinal and automated chemistry tech-affinities in the 30 to several hundred nanomolar range,
thus connecting PPAR and adipose tissue to insulin niques, such synthetic ligands have subsequently been
used as tools to decipher receptor function. A recentsensitivity and type II diabetes [26].
Like many orphan NRs, LXRwas cloned on the basis example of this process is the use of the synthetic
PPAR ligand GW501516 to uncover a role for this re-of DNA sequence homology, and subsequent expres-
sion profiling identified the liver, kidney, and intestine ceptor in the regulation of -oxidation and inflammation
[37]. At the time of writing, using the methods describedas sites of significant expression [27]. Genetic ablation
of LXR produces mice that appear normal; however, in this review, natural or synthetic ligands have been
identified for approximately 60% of the mammalian nu-when challenged with a cholesterol-rich diet, LXR/
mice accumulate massive amounts of cholesterol in the clear receptor family.
liver. This disturbance in cholesterol homeostasis arises
from a failure to upregulate the catabolism of cholesterol
Nuclear Receptor Ligands: The Next Generationto bile acids and the secretion of cholesterol from
Over the next 5–10 years, we expect that recent develop-the liver to the intestine [28]. The characterization of
ments in understanding NR signaling at the molecularLXR/ mice led to the suggestion that this receptor
level will usher in a new era in ligand identification. Infunctions as a sensor of cholesterol that insures homeo-
particular, we anticipate progress along two fronts: thestasis is maintained when cholesterol levels are ele-
discovery of endogenous ligands for orphan receptorsvated. This hypothesis was further supported by the
and the identification of synthetic ligands with tissue-identification of oxidized forms of cholesterol (oxy-ste-
and/or gene-selective activity.rols) as LXR ligands in extracts from bovine liver using
To identify endogenous nuclear receptor ligands, thea transfection assay that measures the functional activ-
sites of synthesis and/or action need to be determinedity of a GAL4 fusion containing the LXR LBD [29]. More
and sensitive methods of detection need to be available.recently, the ability to regulate cholesterol transport and
The accessibility of highly sensitive mass spectrometersmetabolism via LXR has been exploited to develop syn-
that can detect nanogram quantities of small moleculesthetic LXR ligands that display anti-atherogenic activity
provides an answer to the detection problem. Cell orin animal models [30, 31].
animal tissue extracts can be incubated with recombi-Over the last ten years, similar approaches based
nant receptors, the receptor-ligand complex is than iso-upon the identification of ligands that activate individual
lated via an affinity tag on the receptor, and the boundreceptors have resulted in the “adoption” of a significant
ligand can be detected and identified using a masspercentage of the orphans. In many cases, ligand identi-
spectrometer. Once identified, the specifically boundfication has uncovered previously unexpected signaling
pathways including cholesterol transport and catabo- components can be tested for functional activity using
Review
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Figure 5. Transgenic System for Identifying Sites of Receptor
Activity Figure 6. Coregulator-Selective Recruitment by Different PPAR
Crossing transgenic mice expressing a GAL4-receptor LBD fusion Ligands
protein with mice carrying a -galactosidase reporter with GAL4 Recruitment of SRC-2 by TZDs results in insulin sensitivity and
binding sites results in transactivation (detected by blue color) at adipogenesis. Recruitment of SRC-1 by FMOC-L-leucine preferen-
sites where endogenous ligands are present. See Solomin et al. [43] tially influences insulin activity. See Rocchi et al. [47] for details.
for details.
tamoxifen and roloxifene behave as ER antagonists in
the standard NR assays. Interestingly, several potential breast and as agonists in bone [44, 45]. Crystal struc-
NR ligands have copurified along with recombinant tures of ER bound to these different ligands indicate that
LBDs expressed in bacteria for crystallization studies agonists such as estradiol and SERMS such as tamoxifen
[38–40]. The copurification of bound ligands with orphan promote unique conformational changes in the ER LBD
NRs previously considered to be constitutively active [7, 46]. A consequence of these unique conformations is
has led to the suggestion that some NRs may irreversibly that the individual receptor-ligand complexes exhibit
bind endogenous agonists that lock the receptor in an differential affinities for the numerous coactivators and
active conformation [40]. An extreme example of this corepressors that translate the 3-dimesional structure
irreversible ligand hypothesis is the constitutively active of the receptor-ligand complex into a transcriptional
receptor Nurr1. Structural analysis of this receptor does response. These observations have led to the hypothe-
not detect a small molecule in the binding pocket; in- sis that unique receptor conformations recognize dis-
stead, several bulky hydrophobic amino acid residues tinct coregulators and that the ligand-selective NR-core-
in the region normally occupied by ligands [41, 42] ex- gulator complexes consequently regulate unique sets
tend into the putative binding pocket. Thus, in the case or networks of genes. The characterization of the PPAR
of Nurr1, side chains function as a pseudo-intramolecu- ligand FMOC-L-leucine supports this proposed link be-
lar agonist to lock the receptor in an active conformation. tween receptor conformation, coregulator interactions,
Clearly, additional structural studies and molecular model- and biological response. Like the well-studied TZDs,
ing will be needed to determine if other orphan NRs FMOC-L-leucine functions as an insulin-sensitizing
have binding pockets available for small molecules. agent in animal models of type II diabetes. In contrast to
To complement the identification of endogenous li- the TZDs, however, FMOC-L-leucine does not strongly
gands using mass spectrometry, transgenic approaches promote adipogenesis. Strikingly, binding of FMOC-L-
have recently been exploited to uncover the sites of NR leucine promotes interaction between PPAR and the
activity in vivo. Solomin et al. [43] have described the coactivator SRC-1 while TZD binding favors interaction
creation of reporter mice engineered with -galactosi- between PPAR and SRC-2 (Figure 6) [47]. The ligand-
dase reporter gene linked to a minimal promoter con- selective coactivator recruitment correlates nicely with
taining binding sites for the yeast transcription factor the observation that SRC-2/ mice are resistant to diet-
GAL4. Crossing these reporter mice with transgenics induced obesity, thus genetically linking this coactivator
expressing GAL4 DNA binding domain-NR LBD fusions to adipogenesis [48]. Taken together, these studies sug-
allows activation of the reporter in tissues where the gest that interactions between PPAR and SRC-1 are
receptor of interest is activated by endogenous ligands sufficient to promote insulin sensitivity while interaction
(Figure 5). with SRC-2 is necessary for the adipogenic effects of
PPAR ligands. Since increases in adipose mass may
restrict the clinical utility of the TZDs currently on theTissue- and Gene-Selective Ligands:
The Holy Grail market for diabetes, the ability to limit this unwanted
side effect via coactivator-selective ligands appears toCharacterization of selective estrogen receptor modula-
tors (SERMS) has convincingly illustrated the concept be an attractive alternative.
In the future, the combination of coregulator knockoutof tissue/gene-selective NR ligands. SERMS such as
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mice, RNA interference technologies, and gene expres- interfere with protein-protein interactions arises partly
from the use of chemical libraries developed and refinedsion profiling should simplify the ability to link individual
coregulators to particular NR-regulated biological path- for targets with relatively deep hydrophobic pockets
such as enzymes, proteases, and receptors. Thus, per-ways. This knowledge base will allow targeted assays
based upon NR-coregulator interactions to be devel- haps the greatest challenge to the identification of co-
activator inhibiting ligands will be the creation of noveloped in order to identify ligands that promote coregula-
tor-selective interactions. The ability to multiplex such chemical scaffolds that mimic or resemble  helices
and fit tightly into the shallow groove of the coactivatorassays, for instance using two or more coregulator-
derived receptor interacting domains with different fluo- binding surface. Clearly, structural analysis will be re-
quired to allow development of small molecule peptiderescent tags, should allow high throughput approaches
to be used to identify ligands that promote differential mimetics that can subsequently be optimized via tradi-
tional and automated chemistry methods. Although thecoregulator interactions. Additionally, the use of combi-
natorial chemistry methods along with crystal structures development of coactivator inhibiting ligands is wrought
with many challenges, success in this endeavor will notof receptor-ligand-coregulator complexes will be needed
to rapidly expand and optimize initial lead chemical series only provide a new class of NR ligands but will also
provide a paradigm for targeting other therapeuticallythat demonstrate significant selectivity.
relevant protein-protein interactions.
The completion of fly, worm, mouse, and human ge-
The Coregulator Binding Groove: An Opportunity nome projects over the last five years has served to
for Nontraditional Ligands define the NR family, and now more than ever the atten-
The definition of the coregulator binding region as a tion of the field has shifted toward functional character-
shallow hydrophobic groove on the surface of receptor ization. Excitingly, the ability to exploit a common tech-
LBDs [7, 8, 10] raises the possibility of identifying small nology platform has allowed the rapid identification of
molecules that bind in this groove and competitively natural and synthetic receptor-specific ligands that have
inhibit coregulator interactions. Interestingly, not only uncovered a number of new and unexpected endocrine
would such coregulator inhibiting ligands bind to a dif- signaling pathways. More are likely to follow. Given the
ferent site than traditional ligands, but since formation ability of nuclear receptors to positively impact a number
of the coactivator binding surface requires an agonist- of pathological conditions including cancer, inflamma-
dependent conformational change, such inhibiting li- tion, and metabolic disease, we anticipate in the coming
gands may only bind to agonist-occupied receptors. years that our expanding molecular understanding of
Thus, coregulator-inhibiting ligands would be predicted nuclear receptor function will allow the development of
to function as dominant-negative antagonists that block designer drugs with built-in tissue- or gene-selective
the activity of agonist-occupied receptors. This novel activity that provide improved treatments for human
type of antagonist activity may be particularly useful for disease.
the treatment of androgen-independent prostate can-
cer. Many prostate cancer patients develop resistance
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